Harrow Health, Inc. (HROW) Balance Sheet

The balance sheet has deteriorated sharply over the past ten quarters, with total debt climbing from $191.7M to $300.7M while equity contracted by 75%. This divergence suggests that the company's aggressive acquisition strategy has been funded primarily through debt, and the resulting interest burden is eroding retained earnings, which turned more negative from -$147.5M to -$201.4M. The trend indicates that without a significant improvement in operating profitability, the balance sheet may continue to weaken, potentially constraining future financing options.

The debt-to-equity ratio of 20.26 is exceptionally high, reflecting a balance sheet that is heavily reliant on borrowed capital. This leverage appears to be a result of strategic acquisitions, but the associated interest expenses are likely consuming a significant portion of operating cash flow, which turned negative in Q2 2026. Investors should monitor the company's ability to service this debt, especially if revenue growth stalls or interest rates rise, as refinancing risk could become a material concern.

The modest PP&E and negligible goodwill indicate that Harrow's asset base is not heavily weighted toward physical or acquired intangible assets, which is typical for a specialty pharmaceutical company that relies on intellectual property and commercial infrastructure. The slight decline in PP&E suggests limited capital expenditure, which may be appropriate given the company's focus on sales force expansion rather than manufacturing capacity. However, the lack of significant goodwill implies that acquisitions have not resulted in large premium write-offs, but the equity method investments in non-consolidated entities could still pose valuation risks.

The equity base has been severely depleted, with retained earnings declining from -$147.5M to -$201.4M over the period, reflecting persistent operating losses. Stock-based compensation, which totaled $3.8M in Q2 2026, adds to dilution and further pressures equity. This thin equity cushion means that any additional losses could push the company into negative equity territory, which would be a red flag for creditors and could limit access to additional debt financing.

Despite a healthy current ratio, the company's cash position is being eroded by negative operating cash flow, which turned to -$9.8M in Q2 2026. The cash balance of $83.9M provides a runway of approximately 8-9 quarters at the current burn rate, but this assumes no further deterioration. The liquidity buffer appears adequate for the near term, but investors should monitor whether the second-half acceleration in revenue materializes to reverse the cash outflow trend.